表紙
市場調查報告書

神經纖維瘤II型:開發中產品分析

Neurofibromatoses Type II - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 567361
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
神經纖維瘤II型:開發中產品分析 Neurofibromatoses Type II - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 46 Pages
簡介

本報告提供以神經纖維瘤II型為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

神經纖維瘤II型 - 概要

神經纖維瘤II型 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學、研究機關的開發平台趨勢
  • 企業開發中的產品
  • 在大學、研究機關開發中的產品

神經纖維瘤II型 - 治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發神經纖維瘤II型的治療藥的企業

  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Beta Pharma Inc
  • Lixte Biotechnology Holdings Inc
  • Plex Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc

藥物簡介

神經纖維瘤II型 - 暫停中的計劃

神經纖維瘤II型 - 產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11834IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Pipeline Review, H2 2019, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neurofibromatoses Type II - Overview
    • Neurofibromatoses Type II - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neurofibromatoses Type II - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neurofibromatoses Type II - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Beta Pharma Inc
    • BioXcel Corp
    • Plex Pharmaceuticals Inc
    • Recursion Pharmaceuticals Inc
  • Neurofibromatoses Type II - Drug Profiles
  • Neurofibromatoses Type II - Dormant Projects
  • Neurofibromatoses Type II - Discontinued Products
  • Neurofibromatoses Type II - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neurofibromatoses Type II, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, H2 2019
  • Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, H2 2019
  • Neurofibromatoses Type II - Pipeline by BioXcel Corp, H2 2019
  • Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, H2 2019
  • Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
  • Neurofibromatoses Type II - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Neurofibromatoses Type II, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019